journal article·2018-11-05Open access

Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells

Xiaolong Tang, Chunmei Xie, Zhenyou Jiang, Amin Li, Shiyu Cai, Changhao Hou, Jian Wang, Yong Liang, Dong Ma

Abstract

The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Glycosylation and Glycoproteins Research · Immune Cell Function and Interaction · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical College, Anhui University of Science and Technology, Huainan, China;

Department of Laboratory Medicine, Guangzhou 8th People’s Hospital, Guangzhou Medical University, Guangzhou, China;

Departments of Microbiology and Immunology, Jinan University, Guangzhou, China;

Huai’an Hospital Afliated of Xuzhou Medical College and Huai’an Second Hospital, Huai’an, China;

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Department of Biomedical Engineering, Jinan University, Guangzhou, China

Funding

National Natural Science Foundation of China · Anhui Provincial Science and Technology program · University Natural Science Research Project of Anhui Province · Undergraduate Innovation and Entrepreneurship Training Program · Key Research Program in Huai’an · Jiangsu Medical Talent Youth Program · Huai’an Second People’s Hospital

References (34)

Show source-provided references
1. 10.1038/nrclinonc.2010.18910.1038/nrclinonc.2010.189 ↗
2. 10.1002/ijc.2885210.1002/ijc.28852 ↗
3. 10.1016/j.ejca.2013.05.03110.1016/j.ejca.2013.05.031 ↗
4. 10.1038/modpathol.2009.10410.1038/modpathol.2009.104 ↗
5. 10.18632/oncotarget.1920110.18632/oncotarget.19201 ↗
6. 10.18632/oncotarget.1633110.18632/oncotarget.16331 ↗
7. 10.1080/23723556.2016.115927510.1080/23723556.2016.1159275 ↗
8. 10.18632/oncotarget.1660210.18632/oncotarget.16602 ↗
9. 10.1016/j.canlet.2014.11.01210.1016/j.canlet.2014.11.012 ↗
10. 10.18632/oncotarget.1429910.18632/oncotarget.14299 ↗
11. 10.1016/j.juro.2012.11.01010.1016/j.juro.2012.11.010 ↗
12. 10.1002/ijc.2857910.1002/ijc.28579 ↗
13. 10.1007/s00280-013-2129-610.1007/s00280-013-2129-6 ↗
14. 10.1016/j.biomaterials.2017.10.02510.1016/j.biomaterials.2017.10.025 ↗
15. 10.1016/j.jconrel.2017.10.02210.1016/j.jconrel.2017.10.022 ↗
16. 10.1007/s11095-015-1733-z10.1007/s11095-015-1733-z ↗
17. 10.3390/nano504205410.3390/nano5042054 ↗
18. 10.1186/1471-2407-13-25010.1186/1471-2407-13-250 ↗
19. 10.1186/s11671-015-1112-z10.1186/s11671-015-1112-z ↗
20. 10.1016/j.apsb.2016.09.00510.1016/j.apsb.2016.09.005 ↗
21. 10.1039/C5RA01553G10.1039/C5RA01553G ↗
22. 10.1039/C8NR01291A10.1039/C8NR01291A ↗
23. 10.1016/j.jconrel.2017.03.03810.1016/j.jconrel.2017.03.038 ↗
24. 10.1080/17474086.2017.135016410.1080/17474086.2017.1350164 ↗
25. 10.1111/bjh.1418110.1111/bjh.14181 ↗
26. 10.3892/ijo.2015.306210.3892/ijo.2015.3062 ↗
27. 10.1016/j.cell.2017.02.00410.1016/j.cell.2017.02.004 ↗
28. 10.1016/j.ccell.2017.01.00310.1016/j.ccell.2017.01.003 ↗
29. 10.1038/leu.2015.18510.1038/leu.2015.185 ↗
30. 10.3390/molecules19091430410.3390/molecules190914304 ↗
31. 10.1016/j.clml.2014.01.00710.1016/j.clml.2014.01.007 ↗
32. 10.1039/C6RA27154E10.1039/C6RA27154E ↗
33. 10.2147/IJN.S8012910.2147/IJN.S80129 ↗
34. 10.1038/sj.onc.120834910.1038/sj.onc.1208349 ↗